NCT02018523View on ClinicalTrials.gov

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Lenalidomide

lenalidomide 10mg/day orally until disease progression

Trial Locations (1)

77030

Baylor College of Medicine, Houston

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

collaborator

Baylor College of Medicine

OTHER

lead

Jun Zhang

OTHER